文献速递膀胱癌与上尿路尿路上皮癌

卡介苗无反应性非肌层浸润性膀胱癌中保留膀胱治疗与根治性膀胱切除术的长期结局

Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2024-08-25

该回顾性多中心队列纳入578例符合美国食品药品监督管理局标准的卡介苗无反应性非肌层浸润性膀胱癌患者,28%接受 upfront 根治性膀胱切除术,72%接受保留膀胱治疗。中位随访50个月,两组转移无生存、癌症特异性生存和总生存均无统计学显著差异;保留膀胱治疗组12和24个月高级别复发率分别为37%和52%,进展为肌层浸润性膀胱癌分别为7%和13%。

要点

  • 卡介苗无反应性非肌层浸润性膀胱癌中,初始保留膀胱治疗与 upfront 根治性膀胱切除术的中期生存结局相当。
  • 保留膀胱治疗组12和24个月高级别复发率分别为37%和52%,进展为肌层浸润性膀胱癌分别为7%和13%。
  • 保留膀胱治疗组31.7%后续行根治性膀胱切除术,其中13%发现淋巴结病变,而 upfront 根治性膀胱切除术组为4%(P=0.030)。

核心结论

  • 在经选择的患者队列中,初始保留膀胱治疗的中期生存结局与 upfront 根治性膀胱切除术相当。
  • 复发和进展率随时间推移而升高,尤其是在接受额外线数保留膀胱治疗的患者中。

研究设计与样本

  • 回顾性队列研究,预先设定的数据元素从10个国际中心的卡介苗无反应性非肌层浸润性膀胱癌患者中收集。
  • 经机构审查委员会批准后,纳入符合美国食品药品监督管理局卡介苗无反应性非肌层浸润性膀胱癌标准的患者。
  • 共578例患者,28%接受 upfront 根治性膀胱切除术,72%接受保留膀胱治疗;中位(四分位距)随访50(20-69)个月。
  • 保留膀胱治疗方案包括再次电切或仅监测、重复卡介苗灌注、膀胱内化疗、全身免疫治疗和临床试验。

主要发现

  • 两组转移无生存、癌症特异性生存和总生存均无统计学显著差异。
  • 保留膀胱治疗组12和24个月高级别复发率分别为37%和52%。
  • 保留膀胱治疗组12和24个月进展为肌层浸润性膀胱癌的比例分别为7%和13%。
  • 保留膀胱治疗组31.7%后续行根治性膀胱切除术,其中13%发现淋巴结病变,而 upfront 根治性膀胱切除术组为4%(P=0.030)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the oncological risks of bladder-sparing therapy (BST) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC). PATIENTS AND METHODS: Pre-specified data elements were collected from retrospective cohorts of patients with BCG-unresponsive NMIBC from 10 international sites. After Institutional Review Board approval, patients were included if they had BCG-unresponsive NMIBC meeting United States Food and Drug Administration criteria. Oncological outcomes were collected following upfront RC or BST. BST regimens included re-resection or surveillance only, repeat BCG, intravesical chemotherapy, systemic immunotherapy, and clinical trials. RESULTS: Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow-up was 50 (20-69) months. There were no statistically significant differences in metastasis-free survival, cancer-specific survival, or overall survival between treatment groups. In the BST group, high-grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively. RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030). CONCLUSION: In a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Taylor JI, Kamat AM, O'Donnell MA, et al. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2024. PMID: 39183466. doi:10.1111/bju.16509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。